Manchester Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.78M Buy
19,010
+37
+0.2% +$7.96K 0.62% 24
2026
Q1
$4.13M Sell
18,973
-17
-0.1% -$3.77K 0.59% 26
2025
Q4
$4.34M Sell
18,990
-994
-5% -$226K 0.59% 27
2025
Q3
$4.63M Sell
19,984
-1,905
-9% -$388K 0.63% 24
2025
Q2
$4.06M Sell
21,889
-32
-0.1% -$5.95K 0.53% 30
2025
Q1
$4.59M Sell
21,921
-82
-0.4% -$15.9K 0.56% 33
2024
Q4
$3.91M Sell
22,003
-245
-1% -$45K 0.45% 41
2024
Q3
$4.39M Buy
22,248
+267
+1% +$49.8K 0.51% 35
2024
Q2
$3.77M Sell
21,981
-74
-0.3% -$12.3K 0.45% 40
2024
Q1
$4.02M Buy
22,055
+2,518
+13% +$434K 0.49% 37
2023
Q4
$3.03M Sell
19,537
-688
-3% -$100K 0.41% 40
2023
Q3
$3.01M Sell
20,225
-49
-0.2% -$7.19K 0.45% 38
2023
Q2
$2.73M Sell
20,274
-3,166
-14% -$464K 0.37% 42
2023
Q1
$3.74M Buy
23,440
+2,116
+10% +$324K 0.49% 28
2022
Q4
$3.45M Buy
21,324
+6,491
+44% +$995K 0.51% 32
2022
Q3
$1.99M Buy
14,833
+765
+5% +$110K 0.35% 41
2022
Q2
$2.15M Sell
14,068
-65
-0.5% -$9.93K 0.37% 39
2022
Q1
$2.29M Hold
14,133
0.33% 43
2021
Q4
$1.91M Buy
14,133
+300
+2% +$35.4K 0.25% 58
2021
Q3
$1.49M Buy
13,833
+1,228
+10% +$140K 0.2% 72
2021
Q2
$1.42M Buy
12,605
+817
+7% +$92K 0.2% 78
2021
Q1
$1.28M Sell
11,788
-81
-0.7% -$8.66K 0.19% 83
2020
Q4
$1.27M Buy
11,869
+50
+0.4% +$4.8K 0.2% 79
2020
Q3
$1.03M Sell
11,819
-3,307
-22% -$311K 0.16% 85
2020
Q2
$1.49M Buy
15,126
+727
+5% +$64K 0.2% 61
2020
Q1
$1.1M Hold
14,399
0.18% 67
2019
Q4
$1.27M Hold
14,399
0.14% 80
2019
Q3
$1.09M Sell
14,399
-443
-3% -$30.4K 0.13% 84
2019
Q2
$1.08M Hold
14,842
0.14% 83
2019
Q1
$1.2M Sell
14,842
-583
-4% -$47.7K 0.15% 69
2018
Q4
$1.43M Hold
15,425
0.22% 47
2018
Q3
$1.46M Hold
15,425
0.21% 49
2018
Q2
$1.43M Buy
15,425
+9,543
+162% +$932K 0.22% 47
2018
Q1
$557K Sell
5,882
-557
-9% -$61.2K 0.09% 124
2017
Q4
$623K Hold
6,439
0.09% 112
2017
Q3
$572K Hold
6,439
0.09% 109
2017
Q2
$467K Hold
6,439
0.07% 117
2017
Q1
$420K Sell
6,439
-750
-10% -$47.2K 0.07% 127
2016
Q4
$450K Sell
7,189
-856
-11% -$52.3K 0.07% 122
2016
Q3
$507K Sell
8,045
-1,553
-16% -$101K 0.08% 121
2016
Q2
$594K Sell
9,598
-1,000
-9% -$60.9K 0.08% 106
2016
Q1
$605K Sell
10,598
-599
-5% -$33.4K 0.08% 104
2015
Q4
$663K Hold
11,197
0.09% 93
2015
Q3
$609K Hold
11,197
0.1% 83
2015
Q2
$752K Hold
11,197
0.12% 79
2015
Q1
$655K Sell
11,197
-1,740
-13% -$105K 0.1% 85
2014
Q4
$847K Sell
12,937
-1,740
-12% -$110K 0.11% 80
2014
Q3
$848K Buy
14,677
+1,083
+8% +$60.1K 0.11% 74
2014
Q2
$767K Sell
13,594
-50
-0.4% -$2.62K 0.1% 91
2014
Q1
$701K Buy
13,644
+700
+5% +$35.4K 0.11% 100
2013
Q4
$684K Sell
12,944
-670
-5% -$32.9K 0.11% 100
2013
Q3
$609K Sell
13,614
-142
-1% -$6.29K 0.1% 105
2013
Q2
$569K Buy
+13,756
New +$602K 0.11% 97

Other funds holding ABBV

Manchester Capital Management's ABBV Position: Q2 2026 in Review

Manchester Capital Management increased its AbbVie (ABBV) stake by 0.2% in Q2 2026, buying an estimated $7.96K and bringing the position to 19,010 shares worth $4.78M. The position accounts for 0.62% of the portfolio, ranked #24.

Manchester Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Manchester Capital Management held 19,010 shares of AbbVie worth $4.78M as of Q2 2026.
  • Manchester Capital Management bought 37 AbbVie shares in Q2 2026, an estimated $7.96K.
  • AbbVie made up 0.62% of Manchester Capital Management's portfolio in Q2 2026, its #24 holding.
  • Manchester Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.